Recombinant adeno-associated virus (rAAV) is derived from a small human parvovirus with
an excellent safety profile. In addition, this viral vector efficiently transduces and supports …

Adeno-associated virus (AAV) vectors are derived from a nonpathogenic and defective
human parvovirus. Although currently unable to display the integration specificity featured by …

Recombinant adeno-associated virus serotype 2 (rAAV2) vectors have shown promise as
therapeutic agents for neurologic disorders. However, intracerebral administration of this …

Over the last few years, a large number of preclinical and clinical studies have demonstrated
the potential of gene therapy applications using adeno‐associated viral (AAV) vectors. Gene …

Adeno-associated virus (AAV) has emerged as a pivotal delivery tool in clinical gene
therapy owing to its minimal pathogenicity and ability to establish long-term gene expression …

Recombinant adeno-associated virus 2 (rAAV2) has been extensively used as a gene
delivery vector for the nervous system. It targets primarily neurons in the nervous system and …

Adeno-associated viral (AAV) vectors are a rapidly emerging gene therapy platform for the
treatment of neurological diseases. In preclinical studies, transgenes encoding therapeutic …

Recombinant adeno-associated viruses (rAAV) are highly efficient vectors for gene delivery
into the central nervous system (CNS). However, host inflammatory and immune responses …

Gene therapy is a novel method under investigation for the treatment of neurological
disorders. Considerable interest has focused on the possibility of using viral vectors to …

Recombinant adeno‐associated virus (rAAV) is a mammalian virus that has been altered to
be used as a gene delivery vehicle. Several changes to the viral genome have made them …